Third Fatality Exposed in China’s Gene Therapy Trials Amid Regulatory Overhaul

Key points

• Endpoints News reveals a third death in China’s IIT framework, involving a patient with an autoimmune disease receiving experimental CAR-T therapy from a biotech startup.
• This incident follows two earlier undisclosed deaths in 2025: a six-year-old girl treated for a non-fatal condition and a boy with Duchenne muscular dystrophy, both dying from severe immune reactions to viral vector-delivered gene therapies.
• China’s Order 818, effective May 2026, introduced stricter standards for IITs, including mandatory large-animal preclinical studies and GMP compliance for drug production, aiming to close previous regulatory gaps.
• Despite the fatalities, industry leaders like Legend Biotech continue to utilize China’s IIT pathway for its speed, while U.S. regulators and lawmakers debate the reliability of Chinese clinical data.
• Experts note that while transparency and disclosure remain critical issues, the new regulations are expected to slow but not halt the use of IITs, as they provide essential early-stage proof-of-concept data for R&D.

Background

In July 2026, media reports exposed the death of a six-year-old girl, Mei, in an experimental base-editing trial at Shanghai Jiao Tong University, sparking an ethics investigation into researcher Zilong Qiu. This incident highlighted significant gaps in oversight and disclosure within China’s biotech sector, echoing past scandals like the He Jiankui gene-edited babies case. The current third fatality, reported in August 2026, adds to a pattern of undisclosed adverse events that has prompted international scrutiny and regulatory tightening.

How outlets are covering it

Fierce Biotech emphasizes that while the deaths exposed systemic gaps, Order 818 has introduced necessary guardrails, and industry confidence in China’s IIT pathway remains strong due to its speed and efficiency. Experts like Aaron Gu and Steve Yang argue that the new regulations standardize practices without eliminating the pathway’s value. In contrast, MedPage Today and Gizmodo focus on the ethical implications of transparency and informed consent, highlighting the desperation of families and the risks of inadequate disclosure. MedPage Today stresses that speed must not compromise ethical guardrails, while Gizmodo experts debate the balance between safety and the urgent need for treatments in rare diseases. Endpoints News provides the factual update on the third death, underscoring the ongoing opacity in China’s trial system.

Why it matters

The revelation of a third death in China’s IITs underscores the critical tension between accelerating medical innovation and ensuring patient safety. As the U.S. considers adopting similar fast-track models, the reliability and transparency of Chinese clinical data are under intense scrutiny. The implementation of Order 818 represents a pivotal shift in regulatory oversight, potentially influencing global standards for gene and cell therapy trials. Failure to address transparency and safety could erode international confidence in China’s biotech sector, while overly restrictive measures could delay life-saving treatments for rare diseases.

What to watch

Regulators and industry stakeholders will monitor the implementation of Order 818, particularly the new filing review procedures under the National Health Commission. Hospitals and sponsors may face delays as they adapt to stricter preclinical and manufacturing requirements. U.S. lawmakers and the FDA will likely reassess the acceptance of Chinese clinical data, potentially impacting cross-border biotech collaborations. Continued scrutiny of adverse event disclosure and transparency will be crucial to restoring public trust in gene therapy trials.